分组1 - Pfizer reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and showing an increase from $0.6 per share a year ago, resulting in an earnings surprise of +34.48% [1] - The company achieved revenues of $14.65 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.35%, and up from $13.28 billion year-over-year [2] - Over the last four quarters, Pfizer has consistently surpassed consensus EPS estimates four times and revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 11.3% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.86 on revenues of $17.37 billion, and for the current fiscal year, it is $3.07 on revenues of $63.4 billion [7] - The Large Cap Pharmaceuticals industry, to which Pfizer belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Company Overview - Eli Lilly (LLY) closed at $762.95, reflecting a -5.59% change from the previous day, which is worse than the S&P 500's daily loss of 0.3% [1] - Over the last month, Eli Lilly's shares increased by 3.67%, outperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Upcoming Earnings - The upcoming earnings report for Eli Lilly is expected on August 7, 2025, with an anticipated EPS of $5.61, representing a 43.11% increase year-over-year [2] - Revenue is forecasted to be $14.75 billion, indicating a 30.49% growth compared to the same quarter of the previous year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $22.05 per share and revenue of $60.55 billion, reflecting increases of +69.75% and +34.43% respectively from the prior year [3] - Recent changes to analyst estimates for Eli Lilly are noted as indicators of optimism regarding the business outlook [3] Stock Performance and Valuation - The Zacks Rank system, which assesses estimate changes, indicates that Eli Lilly currently holds a Zacks Rank of 3 (Hold) [5] - The Zacks Consensus EPS estimate has increased by 0.48% in the past month [5] - Eli Lilly's Forward P/E ratio is 36.64, which is a premium compared to its industry's Forward P/E of 14.23 [5] Industry Context - Eli Lilly operates within the Large Cap Pharmaceuticals industry, which has a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [7] - The average PEG ratio for the Large Cap Pharmaceuticals industry is 1.24, while Eli Lilly's PEG ratio is 1.15 [6]

Core Viewpoint - Merck reported quarterly earnings of $2.13 per share, exceeding the Zacks Consensus Estimate of $2.01 per share, but down from $2.28 per share a year ago, indicating a +5.97% earnings surprise [1][2] Financial Performance - The company posted revenues of $15.81 billion for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.02%, and down from $16.11 billion year-over-year [2] - Over the last four quarters, Merck has surpassed consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance - Merck shares have declined approximately 15.5% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Merck is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $2.41 on revenues of $17.21 billion, and for the current fiscal year, it is $8.87 on revenues of $64.96 billion [7] - The outlook for the industry, particularly the Large Cap Pharmaceuticals sector, is favorable, ranking in the top 26% of over 250 Zacks industries [8]

Company Overview - Johnson & Johnson (JNJ) is headquartered in New Brunswick and operates in the Medical sector, with a stock price change of 13.19% since the start of the year [3]. Dividend Information - The company currently pays a dividend of $1.30 per share, resulting in a dividend yield of 3.18%, which is higher than the Large Cap Pharmaceuticals industry's yield of 2.38% and the S&P 500's yield of 1.52% [3]. - Johnson & Johnson's annualized dividend of $5.20 has increased by 5.9% from the previous year, with an average annual increase of 5.37% over the last 5 years [4]. - The current payout ratio is 52%, indicating that the company paid out 52% of its trailing 12-month earnings per share as dividends [4]. Earnings Growth - The Zacks Consensus Estimate for 2025 earnings per share is $10.83, reflecting a year-over-year earnings growth rate of 8.52% [5]. Investment Appeal - Johnson & Johnson is considered an attractive dividend play and a compelling investment opportunity, currently holding a Zacks Rank of 2 (Buy) [6].

Company Performance - AbbVie (ABBV) closed at $190.58, marking a +2.25% move from the prior day, outperforming the S&P 500's gain of 0.32% [1] - Over the past month, AbbVie shares appreciated by 0.49%, while the Medical sector experienced a loss of 3.4% [1] Upcoming Earnings - AbbVie is expected to release its earnings report on July 31, 2025, with analysts forecasting earnings of $3.02 per share, indicating a year-over-year growth of 13.96% [2] - The consensus estimate anticipates revenue of $15.04 billion, reflecting a 3.97% increase from the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $12.07 per share and revenue of $60.12 billion, representing shifts of +19.27% and +6.72% respectively from the previous year [3] - Recent changes in analyst estimates suggest a favorable outlook on AbbVie's business health and profitability [3] Valuation Metrics - AbbVie is currently trading at a Forward P/E ratio of 15.44, which is a premium compared to the industry average of 14.02 [6] - The company has a PEG ratio of 1.23, aligning with the average PEG ratio of the Large Cap Pharmaceuticals industry [7] Industry Ranking - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Group 1 - Johnson & Johnson reported quarterly earnings of $2.77 per share, exceeding the Zacks Consensus Estimate of $2.66 per share, but down from $2.82 per share a year ago, representing an earnings surprise of +4.14% [1] - The company achieved revenues of $23.74 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.13% and increasing from $22.45 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Group 2 - The stock has gained approximately 7.3% since the beginning of the year, outperforming the S&P 500's gain of 6.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.75 on revenues of $23.17 billion, and for the current fiscal year, it is $10.64 on revenues of $91.33 billion [7] Group 3 - The Zacks Industry Rank indicates that the Large Cap Pharmaceuticals sector is in the top 26% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this category [8] - Johnson & Johnson currently holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6]

Core Insights - Johnson & Johnson (JNJ) reported quarterly earnings of $2.77 per share, exceeding the Zacks Consensus Estimate of $2.66 per share, but down from $2.82 per share a year ago, representing an earnings surprise of +4.14% [1] - The company achieved revenues of $23.74 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.13% and up from $22.45 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.75 on revenues of $23.17 billion, and for the current fiscal year, it is $10.64 on revenues of $91.33 billion [7] Industry Context - The Large Cap Pharmaceuticals industry, to which Johnson & Johnson belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Core Viewpoint - Strong Q2 results from banks and financial firms highlight the importance of monitoring upcoming earnings reports from medical companies, which can serve as a hedge against market volatility [1][2]. Group 1: Johnson & Johnson (JNJ) - Johnson & Johnson is a leader in the Zacks Large Cap Pharmaceuticals Industry, which ranks in the top 29% of over 240 Zacks industries [3]. - The company is expected to report Q2 results on July 16, with EPS projected to dip 5% to $2.66, but shares trade at a reasonable forward earnings multiple of 14.7X [4]. - JNJ has a 3.32% annual dividend yield, above the industry average of 2.57% and the S&P 500's 1.18% [4]. - The bottom line is projected to expand 6% this year, with FY26 EPS forecasted to rise 4% to $11.09 per share [5]. - The Most Accurate estimate for Q2 EPS is $2.72, which is 2% above the Zacks Consensus [5][6]. Group 2: Novartis (NVS) - Novartis is also part of the top-rated Zacks Large Cap Pharmaceuticals Industry and will report Q2 results on July 17 [6]. - Q2 sales are expected to rise 9% year-over-year to $14.04 billion, with EPS projected to increase 21% to $2.38 [8]. - FY25 EPS estimates have slightly increased, with FY26 EPS estimates rising from $9.14 to $9.35 per share [8]. - NVS trades at an attractive forward earnings multiple of 13.5X and offers a 2.14% annual dividend yield [8]. Group 3: Abbott Laboratories (ABT) - Abbott Laboratories will report Q2 results on July 17, with a diversified line of healthcare products [10]. - Q2 earnings are expected to rise 9% to $1.25 per share, with the Most Accurate estimate at $1.27, slightly above the Zacks Consensus [10][12]. - Sales for Q2 are projected to increase nearly 7% to $11.07 billion, with mid to high single-digit growth expected for the annual outlook [10]. - ABT has a forward earnings multiple of 25.6X, near the industry average, and a 1.79% annual dividend yield [11]. Conclusion - The outlook for Johnson & Johnson, Novartis, and Abbott Laboratories suggests these stocks are worthy of consideration, especially in the context of potential market volatility [13].

Core Viewpoint - Novo Nordisk is expected to report strong earnings growth, with a projected EPS of $0.93, reflecting a 43.08% increase year-over-year, and revenue forecasted at $11.83 billion, indicating a 20.47% growth compared to the same quarter last year [2] Group 1: Stock Performance - In the latest trading session, Novo Nordisk's stock rose by 1.89% to $71.01, outperforming the S&P 500, which gained 0.28% [1] - Over the past month, Novo Nordisk shares have decreased by 11.48%, underperforming the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37% [1] Group 2: Earnings Estimates - For the full year, earnings are projected at $3.94 per share and revenue at $50.41 billion, representing increases of 20.12% and 19.76% respectively from the previous year [3] - The Zacks Consensus EPS estimate has increased by 2.61% over the last 30 days, indicating a positive outlook from analysts [5] Group 3: Valuation Metrics - Novo Nordisk is currently trading at a Forward P/E ratio of 17.71, which is higher than the industry average of 13.94, suggesting a premium valuation [6] - The company has a PEG ratio of 1.36, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.25, indicating a relatively favorable growth expectation [7] Group 4: Industry Ranking - The Large Cap Pharmaceuticals industry, which includes Novo Nordisk, has a Zacks Industry Rank of 27, placing it in the top 11% of over 250 industries [7] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Johnson & Johnson (JNJ) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, continuing a strong trend of surpassing expectations in recent quarters [1][6]. Earnings Performance - Johnson & Johnson has consistently exceeded earnings estimates, with an average surprise of 4.89% over the last two quarters [2]. - In the last reported quarter, the company achieved earnings of $2.77 per share, surpassing the Zacks Consensus Estimate of $2.57 per share by 7.78% [3]. - In the previous quarter, the company reported earnings of $2.04 per share against an expectation of $2.00 per share, resulting in a surprise of 2.00% [3]. Earnings Estimates and Predictions - Recent estimates for Johnson & Johnson have been revised upward, indicating a positive Earnings ESP (Expected Surprise Prediction) which suggests a likelihood of an earnings beat [6]. - The current Earnings ESP for Johnson & Johnson is +0.59%, reflecting increased analyst optimism regarding its near-term earnings potential [9]. - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) indicates a strong possibility of another earnings beat in the upcoming report [9]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Earnings ESP metric compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate being more reflective of recent analyst revisions [8].